Table 3

Changes in levels and trends of, and absolute and relative changes in individual price-negotiated medication cost per DDD, procurement volume and spending

Price-negotiated medicationsBaselineChange after interventionChange 6 months after interventionChange at the end of observation
LevelTrendLevelTrendAbsoluteRelative (%)AbsoluteRelative (%)
Cost per DDD (US$/DDD)
Trastuzumab155.57***−1.65***−55.75***−0.26***−57.29***−50.83−59.08***−58.40
Bortezomib460.65***−5.55***−108.07***−0.23***−109.47***−34.59−111.11***−40.02
Recombinant human endostatin228.69***−2.02***−35.62***0.58***−32.12***−18.24−28.04***−17.31
Erlotinib94.15***−1.87***−22.69***1.02***−16.58***−36.48−9.46−29.25
Sorafenib246.21***−1.23*−111.12***−2.51***−126.16***−58.87−143.7***−69.85
Nimotuzumab146.75***−1.98***−26.46***0.57***−23.02***−24.20−19.01−23.40
Rituximab951.44***−7.49***−215.69***3.79***−192.94***−25.50−166.4***−23.62
Bevacizumab198.88***−1.94***−64.31***−0.58***−67.80***−45.68−71.88***−53.30
Fulvestrant26.83***−0.08***−13.30***−0.05***−13.63***−55.05−14.01***−57.89
Lapatinib86.40***−0.10−24.98***−3.09***−43.52***−52.00−65.15***−78.52
Everolimus75.30***−0.33***−27.16***0.12***−26.46***−39.63−25.63***−39.76
Lenalidomide185.76***−0.02−114.32***−0.69***−118.43***−63.94−123.23***−66.59
Apatinib105.38***−0.24**−35.50***−0.15***−36.43***−36.74−37.52***−38.49
Chidamide144.03***−0.64***−38.90***−0.14***−39.74***−31.19−40.73***−33.13
Abiraterone187.17***−0.79***−93.69***0.72***−89.38***−53.67−84.35***−52.39
Volume (no of DDDs)
Trastuzumab93.35***3.75−23.2733.63***178.52***93.59413.94***190.79
Bortezomib7.89***0.51***17.98***−1.34***9.96***47.000.602.41
Recombinant human endostatin21.89***0.31**6.76**0.4***9.17***30.7011.99***37.44
Erlotinib30.23***0.53***2.351.37***10.57***24.0920.17***42.39
Sorafenib21.67***0.2912.965.78***47.64***163.1988.10***282.22
Nimotuzumab26.14***0.3417.74***2.34***31.77***90.6848.13***128.60
Rituximab8.41***0.29***2.341.53***11.53***72.1122.26***123.44
Bevacizumab32.77***1.97***19.62***15.05***109.93***130.83215.3***220.08
Fulvestrant41.79***0.3834.09***16.7***134.26***260.44251.14***463.54
Lapatinib10.25*0.75−7.024.46***19.77**66.5351.02***145.97
Everolimus13.27***−0.10−0.010.41***2.4422.745.30**52.70
Lenalidomide5.84***0.21−5.54*2.3***8.29***72.6924.42***189.26
Apatinib5.34***1.47***0.481.37***8.69***19.9618.27***33.94
Chidamide−0.300.17**4.29***0.63***8.07***198.0412.49***237.57
Abiraterone3.92*0.198.79**6.56***48.17***549.6294.12***934.69
Spending (US$)
Trastuzumab15377.32***310.38**−12360.62***1108.81***−5707.79**−24.342053.848.02
Bortezomib3911.54***128.15***1507.93***−423.41***−1032.53**−14.25−3996.39***−49.09
Recombinant human endostatin4983.48***21.99−276.9937.53***−51.83−0.93210.863.69
Erlotinib2970.76***−32.48***−833.64***40.52***−590.52**−27.77−306.87−16.16
Sorafenib5306.88***37.32*−1882.34***281.62***−192.60−3.071778.75***27.20
Nimotuzumab3974.38***−16.77−0.72157.25***942.8026.652043.57**59.74
Rituximab8350.76***171.62***−2785.27***804.79***2043.47***15.957676.99***54.78
Bevacizumab6962.73***258.54***−4440.06***719.03***−125.89−0.924907.31***31.67
Fulvestrant1126.59***5.97−247.60164.26***737.93***57.571887.71***142.63
Lapatinib877.3***64.37**−682.04−31.6***−871.64***−34.17−1092.84−36.41
Everolimus997.63***−11.09*−296.67**20.01***−176.58−24.89−36.48−5.77
Lenalidomide1201.93***29.48−1353.46***114.9***−664.09−33.74140.196.45
Apatinib596.74***145.21***−1171.08***9.64***−1113.27***−25.46−1045.82***−19.41
Chidamide−44.1815.7**443.86***42.48***698.76***192.00996.14***210.24
Abiraterone735.93***30.16*−54.39483.01***2843.68***187.086224.77***359.58
  • US$ in 2016.

  • *P<0.05, **p<0.01, ***p<0.001.

  • CI, confidence interval; DDD, defined daily doses.